ANI Pharmaceuticals ANIP Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Revenues by Business | ||||||
| Generics and Other | $109.22M+5.5% | $103.49M+4.9% | $98.69M+4.7% | $94.21M-8.6% | $103.04M+23.1% | |
| Rare Disease and Brands | $128.24M-10.7% | $143.57M+11.2% | $129.13M+10.2% | $117.16M+24.5% | $94.08M-12.0% | |
| Net Revenues by Product | ||||||
| Brand royalties and other revenues | $21.54M— | —— | —— | —— | $0— | |
| Brands | $12.33M+0.1% | $12.32M+15.4% | $10.68M-19.1% | $13.2M-47.5% | $25.12M+26.6% | |
| Cortrophin Gel | $75.12M-32.6% | $111.43M+9.4% | $101.85M+24.7% | $81.65M+54.5% | $52.85M-11.0% | |
| Generic pharmaceutical products | $105.4M+4.6% | $100.76M+6.8% | $94.38M+4.5% | $90.3M-8.5% | $98.68M+25.5% | |
| ILUVIEN and YUTIQ | $19.26M-3.0% | $19.84M+19.5% | $16.6M-25.6% | $22.32M+38.5% | $16.11M-41.7% | |
| Other generic revenues | $3.82M— | —— | —— | —— | $4.36M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ANI Pharmaceuticals break its business down?
- ANI Pharmaceuticals (ANIP) reports net revenues by business across 2 parts — Generics and Other and Rare Disease and Brands. Each is extracted from the segment footnotes and tracked over time.
- Where does ANI Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ANI Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
